Adam P. Barker
University of Utah
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Adam P. Barker.
Clinical and Vaccine Immunology | 2013
Jessica Hansen; E. Susan Slechta; Marcellene A. Gates-Hollingsworth; Brandon Neary; Adam P. Barker; Sean K. Bauman; Thomas R. Kozel; Kimberly E. Hanson
ABSTRACT Cryptococcosis is a systemic infection caused by the pathogenic yeasts Cryptococcus neoformans and C. gattii. Detection of cryptococcal capsular antigen (CrAg) in serum and cerebrospinal fluid (CSF) plays an important diagnostic role. We prospectively compared the new Immuno-Mycologics Inc. (IMMY) lateral flow assay (LFA) and enzyme immunoassay (EIA) to our current CrAg test (Premier EIA; Meridian Bioscience Inc.). Discordant samples were retested with the latex-Cryptococcus antigen test (IMMY) and using serotype-specific monoclonal antibodies (MAbs). A total of 589 serum and 411 CSF specimens were tested in parallel. Qualitative agreement across assays was 97.7%. In all, 56 (41 serum and 15 CSF) samples were positive and 921 (527 serum and 394 CSF) samples were negative by all three assays. The 23 discrepant specimens were all Meridian EIA negative. Of 23 discordant specimens, 20 (87.0%) were positive by both the IMMY LFA and EIA, 2 were LFA positive only, and 1 was EIA positive only. Eleven discrepant specimens had adequate volume for latex agglutination (LA) testing; 8 were LA positive, and 3 were LA negative. LA-negative samples (2 CSF samples and 1 serum) had low IMMY LFA/EIA titers (≤1:10). Serotype-specific MAb analysis of the LA-positive samples suggested that these specimens contained CrAg epitopes similar to those of serotype C strains. In conclusion, the IMMY assays showed excellent overall concordance with the Meridian EIA. Assay performance differences were related to issues of analytic sensitivity and possible serotype bias. Incomplete access to patient-level data combined with low specimen volumes limited our ability to fully resolve discrepant results.
Journal of Clinical Microbiology | 2014
Kimberly E. Hanson; E. S. Slechta; H. Muir; Adam P. Barker
ABSTRACT The erm(41) gene causes inducible macrolide resistance in Mycobacterium abscessus but not Mycobacterium chelonae. erm(41) sequencing of 285 M. abscessus and 45 M. chelonae isolates was compared to 14-day susceptibility; agreement percentages were 98.9% and 100%, respectively. Extended incubation may not be necessary for M. chelonae, and the erm(41) genotype is a useful adjunct for M. abscessus.
Journal of Clinical Microbiology | 2015
Barbara A. Brown-Elliott; Kimberly E. Hanson; Sruthi Vasireddy; Elena Iakhiaeva; Kevin A. Nash; Ravikiran Vasireddy; Nicholas Parodi; Terry Smith; Martha Gee; Anita Strong; Adam P. Barker; Samuel M. Cohen; Haleina Muir; E. Susan Slechta; Richard J. Wallace
ABSTRACT Macrolide resistance has been linked to the presence of a functional erythromycin ribosomal methylase (erm) gene in most species of pathogenic rapidly growing mycobacteria (RGM). For these Mycobacterium isolates, extended incubation in clarithromycin is necessary to determine macrolide susceptibility. In contrast, the absence of a detectable erm gene in isolates of M. chelonae, M. senegalense, and M. peregrinum and a nonfunctional erm gene in M. abscessus subsp. massiliense and 15% to 20% of M. abscessus subsp. abscessus isolates renders these species intrinsically macrolide susceptible. Not all RGM species have been screened for the presence of an erm gene, including the Mycobacterium mucogenicum group (M. mucogenicum, M. phocaicum, and M. aubagnense) and Mycobacterium immunogenum. A total of 356 isolates of these two pathogenic RGM taxa from two reference laboratories (A.R.U.P. Reference Laboratories and the Mycobacteria/Nocardia Laboratory at the University of Texas Health Science Center at Tyler) underwent clarithromycin susceptibility testing with readings at 3 to 5 days and 14 days. Only 13 of the 356 isolates had resistant clarithromycin MICs at initial extended MIC readings, and repeat values on all available isolates were ≤2 μg/ml. These studies suggest that these two additional RGM groups do not harbor functional erm genes and, like M. chelonae, do not require extended clarithromycin susceptibility testing. We propose to the Clinical Laboratory and Standards Institute that isolates belonging to these above-mentioned six rapidly growing mycobacterial groups based on molecular identification with no known functional erm genes undergo only 3 to 5 days of susceptibility testing (to exclude mutational resistance).
Journal of Clinical Microbiology | 2012
Adam P. Barker; Keith E. Simmon; Samuel M. Cohen; E. S. Slechta; Mark A. Fisher; Robert Schlaberg
ABSTRACT No clinical isolates have been reported for the recently described thermoactinomycete Kroppenstedtia eburnea. Between 2006 and 2011, we obtained 14 clinical isolates from patients in 9 U.S. states. Here we report growth characteristics, 16S rRNA gene sequencing, matrix-assisted laser desorption ionization–time of flight (MALDI-TOF) mass spectrometry-based identification, and antimicrobial susceptibility profiles of this recently described organism.
European Journal of Immunology | 2017
Zemin Zhou; Eduardo Reyes-Vargas; Hernando Escobar; Kuan Y. Chang; Adam P. Barker; Alan L. Rockwood; Julio Delgado; Xiao He; Peter E. Jensen
HLA‐DM and class II associated invariant chain (Ii) are key cofactors in the MHC class II (MHCII) antigen processing pathway. We used tandem mass spectrometry sequencing to directly interrogate the global impact of DM and Ii on the repertoire of MHCII‐bound peptides in human embryonic kidney 293T cells expressing HLA‐DQ molecules in the absence or presence of these cofactors. We found that Ii and DM have a major impact on the repertoire of peptides presented by DQ1 and DQ6, with the caveat that this technology is not quantitative. The peptide repertoires of type 1 diabetes (T1D) associated DQ8, DQ2, and DQ8/2 are altered to a lesser degree by DM expression, and these molecules share overlapping features in their peptide binding motifs that are distinct from control DQ1 and DQ6 molecules. Peptides were categorized into DM‐resistant, DM‐dependent, or DM‐sensitive groups based on the mass spectrometry data, and representative peptides were tested in competitive binding assays and peptide dissociation rate experiments with soluble DQ6. Our data support the conclusion that high intrinsic stability of DQ‐peptide complexes is necessary but not sufficient to confer resistance to DM editing, and provide candidate parameters that may be useful in predicting the sensitivity of T‐cell epitopes to DM editing.
Open Forum Infectious Diseases | 2015
Brian A. Kendall; Adam P. Barker; Jason C. Hadley; Scott R. Florell; Kevin L. Winthrop
International travel for the purpose of receiving medical care is increasing. We report a case of disseminated mycobacterial infection after fetal stem cell infusion.
Journal of Clinical Microbiology | 2018
Barbara A. Body; Melodie A. Beard; E. Susan Slechta; Kimberly E. Hanson; Adam P. Barker; N. Esther Babady; Tracy McMillen; Yi-Wei Tang; Barbara A. Brown-Elliott; Elena Iakhiaeva; Ravikiran Vasireddy; Sruthi Vasireddy; Terry J. Smith; Richard J. Wallace; Stuart J. Turner; Lesley H. Curtis; Susan M. Butler-Wu; Jenna Rychert
ABSTRACT This multicenter study was designed to assess the accuracy and reproducibility of the Vitek MS v3.0 matrix-assisted laser desorption ionization–time of flight (MALDI-TOF) mass spectrometry system for identification of Mycobacterium and Nocardia species compared to DNA sequencing. A total of 963 clinical isolates representing 51 taxa were evaluated. In all, 663 isolates were correctly identified to the species level (69%), with another 231 (24%) correctly identified to the complex or group level. Fifty-five isolates (6%) could not be identified despite repeat testing. All of the tuberculous mycobacteria (45/45; 100%) and most of the nontuberculous mycobacteria (569/606; 94%) were correctly identified at least to the group or complex level. However, not all species or subspecies within the M. tuberculosis, M. abscessus, and M. avium complexes and within the M. fortuitum and M. mucogenicum groups could be differentiated. Among the 312 Nocardia isolates tested, 236 (76%) were correctly identified to the species level, with an additional 44 (14%) correctly identified to the complex level. Species within the N. nova and N. transvalensis complexes could not always be differentiated. Eleven percent of the isolates (103/963) underwent repeat testing in order to get a final result. Identification of a representative set of Mycobacterium and Nocardia species was highly reproducible, with 297 of 300 (99%) replicates correctly identified using multiple kit lots, instruments, analysts, and sites. These findings demonstrate that the system is robust and has utility for the routine identification of mycobacteria and Nocardia in clinical practice.
Journal of Clinical Microbiology | 2014
Adam P. Barker; Keith E. Simmon; Sam Cohen; Audrey N. Schuetz; E. Susan Slechta; Mark A. Fisher; Robert Schlaberg
Volume 50, no. 10, p. [3391–3394][1], 2012. Page 3391: The byline and affiliation line should appear as shown above. [1]: /lookup/doi/10.1128/JCM.01186-12
Medical Mycology | 2014
Adam P. Barker; Jennifer L. Horan; E. Susan Slechta; Barbara D. Alexander; Kimberly E. Hanson
The Journal of Applied Laboratory Medicine: An AACC Publication | 2018
Natalie N. Rasmussen; Adam P. Barker; Frederick G. Strathmann